Correction: The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer

Yusuke Shiozawa; Janice E. Berry; Matthew R. Eber; Younghun Jung; Kenji Yumoto; Frank C. Cackowski; Hyeun Joong Yoon; Princy Parsana; Rohit Mehra; Jingcheng Wang; Samantha McGee; Eunsohl Lee; Sunitha Nagrath; Kenneth J. Pienta; Russell S. Taichman

doi:10.18632/oncotarget.18369

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer

Yusuke Shiozawa, Janice E. Berry, Matthew R. Eber, Younghun Jung, Kenji Yumoto, Frank C. Cackowski, Hyeun Joong Yoon, Princy Parsana, Rohit Mehra, Jingcheng Wang, Samantha McGee, Eunsohl Lee, Sunitha Nagrath, Kenneth J. Pienta and Russell S. Taichman _

PDF | How to cite

Oncotarget. 2017; 8:38075-38075. https://doi.org/10.18632/oncotarget.18369

Metrics: PDF 2260 views | ?

Present: The original figure 7 misspelled the word 'rapamycin'.

Corrected: The proper spelling appears in the figure below. The authors sincerely apologize for this error.

Original article: Oncotarget. 2016; 7:41217-32. DOI: 10.18632/oncotarget.9251.

Figure 7: Model system for the induction of a CSC phenotype in marrow by the HSC niche. Prostate cancer cells preferably spread to the bone and survive within the marrow microenvironment for a long period of time. However, the mechanisms underlying the survival of these disseminated tumor cells (DTCs) remain unclear. Our previous work revealed that prostate cancer DTCs target the osteoblastic hematopoietic stem cell (HSC) niche, and that these DTCs parasitize the niche to survive there. The major function of the niche is maintaining the stem cell phenotype. This study demonstrated that the conversion of cancer cells to stem-like cancer cells (CSC) occurs when DTCs directly contact the osteoblastic niche. GAS6 expressed by the osteoblastic niche activates mTOR signaling in the prostate cancer DTCs through the Mer receptor, contributing to the conversion to CSCs. Furthermore, our data suggests that these activations uniquely progress first through mTORC2 and then mTORC1, which can be blocked by rapamycin. Therefore, targeting mTOR signaling in DTCs could be a promising therapy for bone metastatic disease.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18369

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer